Pharmacy Audit Defense: PBM Recoupment and Medicaid Pharmacy Audits Explained

How pharmacy benefit manager audits and Medicaid pharmacy audits work, what triggers recoupment, how state fair pharmacy audit laws and the 2026 federal PBM reforms affect pharmacies, and the documentation and appeal strategies that protect pharmacy revenue.

KNOWLEDGE CENTER

11/15/202612 min read

For many community and specialty pharmacies, audits are not an occasional event but a constant feature of doing business. Pharmacy benefit managers (PBMs) audit claims on behalf of commercial health plans, Medicare Part D plans, and Medicaid managed care organizations. State Medicaid agencies, their recovery audit contractors, and Medicaid Fraud Control Units review fee-for-service pharmacy claims. Federal contractors and the HHS Office of Inspector General (OIG) examine Part D and Medicaid prescription drug billing. Each of these reviewers can demand repayment, and some can terminate network participation or refer cases for investigation.

Pharmacy audits are distinctive in how much money can turn on small details. A prescription that was dispensed correctly to the right patient may still produce a full recoupment of the ingredient cost if the days' supply was miscalculated, the prescriber's identifier was missing, or the pharmacy cannot produce wholesaler invoices showing it purchased enough of the drug. Because pharmacies operate on thin margins and high-cost specialty drugs can be worth thousands of dollars per fill, a single audit can threaten a pharmacy's viability.

The legal landscape is also changing. Most states have enacted fair pharmacy audit laws that limit recoupment for clerical errors and restrict extrapolation, and several states, including Delaware in September 2026, added new protections this year. In February 2026, Congress enacted the most significant federal PBM reforms in decades as part of the Consolidated Appropriations Act, 2026, although most of the Medicare Part D changes do not take effect until 2028 and 2029.

This article explains the types of pharmacy audits, common findings, the legal protections available to pharmacies, and practical strategies for responding and appealing. It is educational and not legal advice. Pharmacy audit rules vary by state, payer, and contract, so pharmacies should consult experienced healthcare counsel about their specific situations.

Who Audits Pharmacies

PBMs on Behalf of Plan Sponsors

PBMs administer prescription drug benefits for commercial insurers, self-funded employer plans, Medicare Part D sponsors, and Medicaid managed care plans. Pharmacy network agreements and provider manuals typically grant PBMs broad audit rights, including desk audits, on-site audits, invoice reconciliation audits, and investigations by special investigation units. The PBM's contract with the plan sponsor often gives the PBM financial incentives to identify and recover overpayments, which pharmacies frequently cite as a source of aggressive audit practices.

State Medicaid Programs

State Medicaid agencies audit fee-for-service pharmacy claims through their own program integrity units, Medicaid recovery audit contractors, and other contractors. State Medicaid Fraud Control Units investigate and prosecute provider fraud. In states where most Medicaid beneficiaries are enrolled in managed care, pharmacy claims are often processed by the managed care organization's PBM, and audits are conducted by that PBM or the plan's special investigation unit, sometimes alongside state oversight.

Federal Reviewers

Medicare Part D sponsors and their PBMs are responsible for oversight of Part D pharmacy claims, but federal contractors, including the Investigations Medicare Drug Integrity Contractor, also analyze Part D data and investigate potential fraud. OIG audits and evaluations have examined Part D and Medicaid prescription drug billing, and DOJ prosecutes pharmacy fraud schemes, often as part of national health care fraud takedowns.

Types of Pharmacy Audits

Desk Audits

In a desk audit, the auditor requests copies of prescriptions, signature logs, and other records for a sample of claims, and the pharmacy submits them electronically or by mail. Desk audits often focus on specific claim elements, such as days' supply, prescriber information, or dispense-as-written codes.

On-Site Audits

On-site audits involve auditors visiting the pharmacy to review original prescriptions, inspect records, and sometimes interview staff. On-site audits can cover a larger number of claims and may include review of operations, licensure, and compliance with the network agreement.

Invoice Reconciliation Audits

Invoice audits, sometimes called inventory or purchase audits, compare the quantity of a drug the pharmacy billed to the plan during a period with the quantity the pharmacy purchased from approved wholesalers or manufacturers. If billed quantities exceed documented purchases, the auditor may treat the difference as a shortage and recoup payment for all claims it cannot reconcile. These audits can produce large recoupments, especially for high-cost drugs.

Fraud, Waste, and Abuse Investigations

PBM special investigation units investigate suspected fraud, often triggered by data analytics, tips, or unusual billing patterns. These investigations may involve extensive records requests, patient verification, prescriber verification, and interviews, and they can lead to termination from networks and referrals to law enforcement.

Medicaid Program Integrity Audits

Medicaid audits examine compliance with state Medicaid pharmacy requirements, which may include prior authorization, preferred drug lists, tamper-resistant prescription requirements, prescriber enrollment, quantity limits, and lock-in programs. Medicaid audits may use statistical sampling and extrapolation where state law permits.

Common Audit Findings

Days' Supply Errors

Incorrectly calculated days' supply is one of the most frequent findings. It is common for products such as insulin, inhalers, eye drops, topical medications, and drugs with variable dosing, where the correct days' supply depends on the prescribed dose and package size. Overstated days' supply can allow refills that appear early, while understated days' supply can allow the pharmacy to dispense more frequently than the plan permits.

Missing or Incorrect Prescriber Information

Claims may be denied if the prescriber's National Provider Identifier is missing or incorrect, if the prescriber was not authorized to prescribe the drug, or if the prescriber was excluded or not enrolled where enrollment is required. Medicaid programs and Medicare Part D require prescribers to meet certain enrollment or validity requirements.

Prescription Validity

Auditors check whether prescriptions meet state and federal requirements, including required elements, signatures, dates, and controlled substance rules. Medicaid fee-for-service programs require written prescriptions to be executed on tamper-resistant pads, with exceptions for electronic, faxed, and telephone prescriptions.

Dispense-as-Written and Product Selection Codes

Incorrect dispense-as-written codes can affect reimbursement, particularly when a brand drug was dispensed and billed at brand rates without documentation that the prescriber or patient required the brand.

Quantity and Refill Issues

Auditors look for quantities that exceed the prescription, refills dispensed beyond those authorized, and refills dispensed after a prescription expired.

Proof of Delivery and Signature Logs

Auditors require evidence that the patient or an authorized representative received the medication, such as signature logs for pickup or delivery records for mail and courier delivery. Missing proof of delivery is a frequent cause of recoupment.

Invoice Shortages

Invoice audits frequently identify shortages because the pharmacy purchased drugs from wholesalers the PBM does not recognize, because invoices were incomplete, or because purchases were shared among affiliated pharmacies without adequate documentation.

Compounding and Specialty Drugs

Compounded medications and specialty drugs carry higher payment amounts and receive heightened scrutiny. Auditors examine ingredient sourcing, billing of ingredients, medical necessity, and compliance with plan restrictions.

State Fair Pharmacy Audit Laws

What These Laws Do

Most states have enacted fair pharmacy audit laws that regulate how PBMs and other auditing entities conduct pharmacy audits. Common protections include:

• Advance notice of on-site audits, often at least seven to fourteen days.

• Limits on audit frequency and the look-back period, often two years from the date of the claim.

• Requirements that audits involving clinical or professional judgment be conducted by or in consultation with a licensed pharmacist.

• Prohibitions or limits on extrapolation.

• Restrictions on recoupment for clerical or recordkeeping errors that do not result in financial harm.

• Rights to correct clerical errors by submitting amended claims.

• Deadlines for preliminary and final audit reports.

• Defined appeal processes.

• Prohibitions on auditing during the first days of a month, when prescription volume is high.

• Requirements that auditors accept certain records, such as electronic records or invoices from wholesalers that are licensed under state law.

Examples

The details vary considerably. Texas law, for example, provides that a PBM may not base recoupment on the absence of documentation that is not required by law, and that an unintentional clerical or recordkeeping error may not be the basis of recoupment unless it results in actual financial harm. Oklahoma's Pharmacy Audit Integrity Act provides that clerical or recordkeeping errors, such as typographical errors, scrivener's errors, and computer errors, are not to be treated as fraud. Kentucky's audit law limits extrapolation and prohibits recoupment for non-material clerical errors absent fraud. In September 2026, Delaware enacted Senate Bill 271, which adds new audit limits, expanded appeal rights, and anti-retaliation protections, and legislatures in other states, including Florida, Missouri, and Hawaii, considered further audit reforms in 2026.

Scope Limitations

Fair audit laws generally apply to commercial insured plans and, in many states, to Medicaid managed care plans. Their application to self-funded employer plans governed by ERISA has been contested. In Rutledge v. Pharmaceutical Care Management Association, decided in 2020, the U.S. Supreme Court held that ERISA did not preempt an Arkansas law regulating PBM reimbursement, which strengthened states' ability to regulate PBMs, but later decisions have found that some state PBM provisions are preempted as applied to ERISA plans. State audit laws also generally do not govern Medicare Part D, because federal law preempts many state laws as applied to Part D plans. Pharmacies should determine which law applies to each audited claim based on the type of plan involved.

Enforcement

Enforcement mechanisms differ. Some states give their insurance department or board of pharmacy authority to investigate complaints and penalize PBMs, and some provide private rights of action. In other states, enforcement has been limited, although pharmacies can still cite the law in disputing audit findings. Pharmacies should know how to file complaints with the appropriate state agency.

Federal PBM Reform in 2026

The Consolidated Appropriations Act, 2026, signed on February 3, 2026, includes major PBM reforms. For Medicare Part D, the law delinks PBM compensation from drug prices, requires pass-through of manufacturer remuneration, expands plan sponsors' rights to audit PBMs, and strengthens any willing pharmacy requirements by directing CMS to establish standards for reasonable and relevant contract terms. For commercial plans, it increases PBM transparency and reporting obligations to plan sponsors. Most Part D provisions begin with the 2028 plan year, and certain network provisions begin in 2029.

These reforms do not directly regulate PBM audits of pharmacies in the way state fair audit laws do, but they may affect the network and contracting environment in which audits occur. Pharmacies should review their Part D network agreements as the new standards are implemented and track CMS rulemaking on reasonable and relevant contract terms.

Medicaid Pharmacy Audits

Medicaid Requirements Auditors Check

Medicaid pharmacy audits examine compliance with federal and state requirements, including:

• Tamper-resistant prescription requirements for written prescriptions in fee-for-service Medicaid under section 1903(i)(23) of the Social Security Act.

• Prescriber enrollment requirements under 42 CFR 455.410, which require ordering and prescribing practitioners to be enrolled in Medicaid.

• Prior authorization and preferred drug list requirements.

• Quantity limits and early refill edits.

• Lock-in program restrictions limiting certain beneficiaries to a single pharmacy or prescriber.

• Coordination of benefits, including billing other insurance first.

• State-specific documentation and record retention rules.

Medicaid Recovery Audits and Extrapolation

Medicaid recovery audit contractors and state program integrity units may use statistical sampling and extrapolation, subject to state law and their contracts. Pharmacies should review sampling methodologies carefully and challenge flawed methods.

Medicaid Fraud Control Units

Medicaid Fraud Control Units investigate allegations of pharmacy fraud, such as billing for drugs not dispensed, billing brand drugs while dispensing generics, kickbacks, and diversion. Contact from a Medicaid Fraud Control Unit requires immediate engagement of counsel.

Responding to a Pharmacy Audit

Review the Notice and Contract

When an audit notice arrives, review it to identify the auditor, the plan sponsor, the claims involved, the deadline, and the type of audit. Review the network agreement and provider manual for audit procedures, appeal rights, and record requirements. Identify which state laws apply.

Assert Statutory Rights

If the audit does not comply with applicable fair audit laws, such as by failing to give adequate notice, exceeding the look-back period, or scheduling during prohibited days, raise the issue in writing promptly.

Gather Complete Documentation

For each claim, gather the original prescription, any prescriber communications documenting clarifications, the dispensing record, proof of delivery or signature logs, prior authorization approvals, and, for invoice audits, complete wholesaler and manufacturer invoices, credit memos, and records of transfers between pharmacies. Organize documents clearly and keep copies of everything submitted.

Respond to the Preliminary Report

Most audits produce a preliminary report with findings and an opportunity to respond. Dispute every finding that can be disputed. Provide additional documentation, explain clinical rationale, and cite applicable state laws, especially protections against recoupment for clerical errors. Request amended claim opportunities for correctable errors where state law or the contract allows.

Appeal the Final Report

If findings stand after the preliminary response, use the appeal process in the contract and state law. Some states provide external appeal rights through a state agency. Keep track of deadlines and escalate where appropriate.

Challenge Extrapolation

If the auditor extrapolated findings, review whether extrapolation is permitted under state law or the contract and whether the methodology is statistically valid. Many state laws prohibit extrapolation in PBM audits.

Consider Complaints and Legal Action

If a PBM's audit practices violate state law, pharmacies can file complaints with the state insurance department, board of pharmacy, or attorney general. In significant cases, legal action may be warranted.

Engage Counsel for Fraud Allegations

If an audit involves allegations of fraud, termination from the network, or contact from law enforcement, engage counsel immediately and avoid making statements without legal advice.

Building an Audit-Ready Pharmacy

• Train staff to calculate days' supply accurately for complex products and document calculations.

• Verify prescriber information and enrollment at dispensing.

• Document prescription clarifications with prescribers, including the date, time, person spoken with, and change made.

• Maintain complete signature logs and delivery records.

• Purchase from wholesalers recognized by PBMs, and retain complete invoices and credit memos for the full audit look-back period.

• Monitor claims for high-risk drugs and billing patterns.

• Conduct internal audits using PBM criteria.

• Keep a calendar of audit deadlines and contract renewal dates.

• Review network agreements for audit terms and negotiate where possible.

• Report and return identified overpayments as required for government programs.

Network Termination and Retaliation Risk

Audit findings can have consequences beyond recoupment. Network agreements commonly allow PBMs to terminate pharmacies for audit failures, credentialing problems, or suspected fraud, and termination from a major PBM network can cut off access to a large share of a pharmacy's patients. Pharmacies should treat repeated findings, even small ones, as a warning sign and correct underlying problems promptly. When termination is threatened, pharmacies should review the contract's notice, cure, and appeal provisions, document their corrective actions, and consider whether state law offers protections. Some state laws, including Delaware's 2026 statute, prohibit PBMs from retaliating against pharmacies that file complaints or exercise their legal rights, and pharmacies should be aware of these protections when deciding whether to report noncompliant audit practices.

Common Mistakes

• Missing audit deadlines.

• Accepting preliminary findings without dispute.

• Failing to cite state fair audit law protections.

• Purchasing from secondary sources without adequate documentation.

• Failing to retain invoices for the full look-back period.

• Submitting incomplete records or original documents without copies.

• Responding to fraud investigations without counsel.

Myths About Pharmacy Audits

Myth: If the Patient Received the Correct Drug, There Is No Recoupment

PBMs often recoup for technical errors even when the correct drug was dispensed. State laws may limit this, but pharmacies must assert those protections.

Myth: State Audit Laws Apply to Every Plan

State laws generally apply to insured commercial plans and often to Medicaid managed care, but their application to self-funded ERISA plans and Medicare Part D is limited.

Myth: Federal PBM Reform Stops Audit Recoupment

The 2026 federal reforms address PBM compensation, transparency, and network access, and most take effect in 2028 and 2029. They do not eliminate pharmacy audits.

Myth: Small Findings Are Not Worth Disputing

Small findings can be extrapolated or used to support network termination, so disputing every finding protects the pharmacy.

Questions Leadership Should Ask

• Do we know which state audit laws apply to our claims?

• Are our days' supply calculations accurate for complex products?

• Do we retain complete wholesaler invoices for the full look-back period?

• Do we dispute every questionable finding?

• Are our network agreements' audit provisions understood and monitored?

• How do we respond to fraud investigations?

Key Takeaways

• Pharmacies face audits from PBMs, state Medicaid programs, and federal reviewers, including desk, on-site, invoice, and fraud audits.

• Common findings include days' supply errors, prescriber issues, missing proof of delivery, and invoice shortages.

• State fair pharmacy audit laws limit recoupment for clerical errors, restrict extrapolation, and provide appeal rights, but their scope varies by plan type.

• The 2026 federal PBM reforms change Part D compensation and network rules mostly beginning in 2028 and 2029.

• Thorough documentation, prompt responses, assertion of legal rights, and appeals are critical to pharmacy audit defense.

How HealthBridge Can Help

HealthBridge helps independent, specialty, and institutional pharmacies prepare for and respond to PBM and Medicaid audits. Our team can review audit notices and network agreements, identify applicable state audit protections, organize documentation and invoice reconciliations, prepare responses to preliminary findings and appeals, and conduct internal audits using PBM criteria. We also help pharmacies strengthen days' supply, prescriber verification, and recordkeeping practices. If your pharmacy is facing an audit or recoupment demand, please get in touch with us. We will be happy to help you with this topic.

References

• Congress.gov. H.R. 7148, Consolidated Appropriations Act, 2026 (Public Law, signed February 3, 2026). https://www.congress.gov/bill/119th-congress/house-bill/7148

• Texas Legislature. Texas Insurance Code Chapter 1369, Subchapter F, Pharmacy Benefit Managers and Audits (Sec. 1369.251 et seq.). https://statutes.capitol.texas.gov/Docs/IN/htm/IN.1369.htm

• Oklahoma Legislature. SB 993 (2025–2026), amending the Pharmacy Audit Integrity Act. https://www.oklegislature.gov/BillInfo.aspx?Bill=SB993&Session=2600

• Kentucky General Assembly. Kentucky Revised Statutes 304.17A-740 et seq. https://apps.legislature.ky.gov/law/statutes/

• Delaware General Assembly. Senate Bill 271 (153rd General Assembly, signed September 8, 2026). https://legis.delaware.gov/

• Florida Senate. SB 1256 (2026) Bill Analysis. https://flsenate.gov/Session/Bill/2026/1256

• Hawaii State Legislature. H.B. 1643 (2026), Relating to Pharmacy. https://data.capitol.hawaii.gov/sessions/session2026/Bills/HB1643_.HTM

• Missouri Senate. SB 984 (2026). https://www.senate.mo.gov/26info/pdf-bill/comm/SB984.pdf

• Supreme Court of the United States. Rutledge v. Pharmaceutical Care Management Association, 592 U.S. 80 (2020). https://www.supremecourt.gov/opinions/20pdf/18-540_m648.pdf

• U.S. Code. 42 U.S.C. 1396b(i)(23), Tamper-resistant prescription pad requirement. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section1396b

• Electronic Code of Federal Regulations. 42 CFR 455.410, Enrollment and screening of providers. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-C/part-455/subpart-E/section-455.410

• Electronic Code of Federal Regulations. 42 CFR 423.505, Contract provisions (Part D record retention and audit). https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-423/subpart-K/section-423.505

• Electronic Code of Federal Regulations. 42 CFR Part 455, Subpart F, Medicaid Recovery Audit Contractors Program. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-C/part-455/subpart-F

• Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 9, Compliance Program Guidelines. https://www.cms.gov/medicare/prescription-drug-coverage/prescriptiondrugcovcontra/downloads/chapter9.pdf

• Centers for Medicare & Medicaid Services. Medicaid Pharmacy: Tamper-Resistant Prescription Pads. https://www.medicaid.gov/medicaid/prescription-drugs/index.html

Some or all of the services described herein may not be permissible for HealthBridge US clients and their affiliates or related entities.

The information provided is general in nature and is not intended to address the specific circumstances of any individual or entity. While we strive to offer accurate and timely information, we cannot guarantee that such information remains accurate after it is received or that it will continue to be accurate over time. Anyone seeking to act on such information should first seek professional advice tailored to their specific situation. HealthBridge US does not offer legal services.

HealthBridge US is not affiliated with any department of public health agencies in any state, nor with the Centers for Medicare & Medicaid Services (CMS). We offer healthcare consulting services exclusively and are an independent consulting firm not affiliated with any regulatory organizations, including but not limited to the Accrediting Organizations, the Centers for Medicare & Medicaid Services (CMS), and state departments. HealthBridge is an anti-fraud company in full compliance with all applicable federal and state regulations for CMS, as well as other relevant business and healthcare laws. The badges, icons, and achievement graphics displayed on this website represent proprietary performance metrics, volume milestones, and internal corporate recognition issued exclusively by our corporate affiliate network at SummitRidge. These visual markers are utilized solely as historical indicators of enterprise growth, operational longevity, and volume-based milestones cleared within our shared corporate ecosystem.

© 2026 HealthBridge US, a California corporation. All rights reserved.

For more information about the structure of HealthBridge, visit www.myhbconsulting.com/governance

Legal

Resources